CureVac names a US subsidiary CEO to advance mRNA work; Sunesis shares slide after regulators nix drug app
→ Germany’s CureVac has named a US CEO to help advance its work on mRNA. And not surprisingly he’ll be based in the Boston/Cambridge hub, where rival Moderna has been attracting attention — of all varieties. “As CEO of CureVac Inc., my goal will be to expand CureVac’s US business entity and to focus the corporate development efforts to grow our business globally,” said Daniel Menichella, who’s taking the post.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.